Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thalassemia × Alemtuzumab × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 54 Leukemia 38 Lymphoma 34 Lymphoma, Non-Hodgkin 20 Precursor Cell Lymphoblastic Leukemia-Lymphoma 19 Hodgkin Disease 19 Myelodysplastic Syndromes 15 Multiple Myeloma 14 Myeloproliferative Disorders 12 Leukemia, Myeloid, Acute 12 Recurrence 10 Lymphoma, Mantle-Cell 10 Lymphoma, Large B-Cell, Diffuse 10 Lymphoma, Follicular 9 Lymphoma, T-Cell, Peripheral 8 Burkitt Lymphoma 8 Anemia, Aplastic 8 Neoplasms, Plasma Cell 7 Lymphoma, B-Cell, Marginal Zone 7 Sezary Syndrome 6 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6 Mycosis Fungoides 6 Lymphoma, T-Cell, Cutaneous 6 Lymphoma, T-Cell 6 Lymphoma, Large-Cell, Immunoblastic 6 Leukemia, Myelomonocytic, Chronic 6 Leukemia, Myeloid, Chronic-Phase 6 Immunoblastic Lymphadenopathy 6 Congenital Abnormalities 6 Waldenstrom Macroglobulinemia 5

Interventions

fludarabine phosphate 2 Cyclophosphamide 2 fludarabine 1 Whole-Body Irradiation 1 Peripheral Blood Stem Cell Transplantation 1 Mesna 1 Busulfan 1 Alemtuzumab 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00578292 2020-05-01

THALLO

Baylor College of Medicine

Phase NA Terminated

10 enrolled 15 charts

Lymphoma, Follicular, Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡